Product Launch Update December 2020

Michael Winlo - MD & CEO

ASX:EMD


myriad data.
individual care.

Disclaimer and notices

This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Presentation release authorised by **Michael Winlo, CEO and Managing Director**





Emyria leads **drug development programs**
backed by uniquely generated **clinical evidence**
while caring for patients with **unmet medical needs**




4 things you need for drug development

New Treatments

Patients in need

Clinicians

Data systems




to answer...

What works?

For who?

Is it safe?

Emyria brings together each of these:



Specific treatments, for specific indications, and safe

Emyria Care



5 sites in Australia

+ 1 clinical partner in UK





3,000 patients

and counting...

A powerful database of unique data insights


Emyria Data


2.6M unique data points

and counting...

2-96 years **age range** of patients	**56%** female patients	**44** unique **primary indications**
54% patients presenting with symptoms of moderate to severe **anxiety**	**53%** patients presenting with symptoms of moderate to severe **depression**	**7.12** average **concomitant medications** per patient at initial visit
0-600mg range of **CBD** prescribed doses are carefully titrated for each patient which gives Emyria unique dose response insights	**0-197**mg range of **THC** prescribed doses are carefully titrated for each patient which gives Emyria unique dose response insights	**35%** patients experiencing an **adverse event**

Data summary as of 01 DEC 2020



Creates
• We have access to patients & clinicians
• We build data management technology
Emyria Care
Accelerates
• We have in-house analytics, clinical trial and drug registration expertise
Emyria Data
Drug registration
• Our clinical evidence supports quality, safety and efficacy evaluations for specific treatments and patient populations to support drug registration efforts
• Our care model supports ongoing monitoring and evaluation
• We learn from every patient to improve care
Informs



Case Study - Bob

- Vietnam Veteran | injured by fall in 1969 | multiple fractures
- Chronic back pain | peripheral neuropathy from Agent Orange | PTSD
- **<u>At initial visit:</u>** oxycontin | buprenorphine | pregabalin | gabapentin | PEA duloxetine – with little relief and side effects.
- **<u>Now</u>**: Stable at 15mg 1:1 THC/CBD | **ceased all opiates**, pregabalin and PEA

Scores	Initial assessment	Visit 5
BPI Pain severity score	5.0	1.75
BPI Pain interference score	5.29	0.86
Visual analogue scale	5.0	1.0
Insomnia severity score	12.0	1.0
DASS 42 Depression	14	4
DASS 42 Anxiety	16	2
DASS 42 Stress	16	12



Why drug registration matters

Medicinal cannabis access in Australia




Medicinal cannabis products are "unregistered" meaning, they are only available to patients via Special Access Schemes, Authorised Prescriber programs or clinical trials*

* **Only 1 product is registered** & **available via routine prescription** (Epidyolex) and only for **rare forms of epilepsy** with an estimated prevalence of 1 in 20k-40k

Source: https://www.tga.gov.au/australian-register-therapeutic-goods

Prescription counts by select drug groupings in Australia in 12 months



Sources: https://www.pbs.gov.au/info/browse/statistics (data from 01 Jul 2018 to 30 Jun 2019
https://www.tga.gov.au/medicinal-cannabis-role-tga (data from 01 Nov 2019 to 31 Oct 2020)


Government payments for select treatments in Australia in 12 months

Registered treatments
(i.e. routine prescription)

Medicinal cannabis
(via Special Access Scheme)

Registered prescriptions can be subsidised by government, reducing out-of-pocket costs to patients

Amounts represent Pharmaceutical Benefit Scheme subsidised payments and government co-payments




Source: https://www.pbs.gov.au/info/browse/statistics (data from 01 Jul 2018 to 30 Jun 2019)

Emyria's drug registration programs:

- Target **unmet medical needs** (i.e large patient populations)
- Backed by unique **clinical evidence:**
    - Dose-response insights
    - Unique IP

How Emyria's model can accelerate drug registration



Emyria's first product - *a cannabinoid for* ***mental health***

Creates

Accelerates

Emyria Care

- **60%** of Emyria's patients
- **4.8M** Australians affected
- **$60B/yr** cost to Australian health system
- COVID-19 has increased demand for new treatments

Emyria Data

<u>Emyria's data provided:</u>

- **Dose response** insights
- **Safety** data
- **Patient stratification**
- Strategic **trial** & **product development** insights

Emyria Rx

- **IP filed**
- Design of pivotal **registration trials** underway
- Conversations with **supply partners** underway

Source: https://www.aph.gov.au/About_Parliament/Parliamentary_Departments/Parliamentary_Library/pubs/rp/rp1819/Quick_Guides/MentalHealth

Emyria's registration pipeline

*Emyria's diverse patient population and **data supports multiple drug registration programs** that can be pursued with **partners** or **independently***


Company / Owner	**Product / Program**	**Target Indication**	**Collect RWE data**	**Data analysis & insights**	**Product dose & form selection**	**Launch registration program**	**Registration**	**Sales**	**Ongoing monitoring**
Who owns the drug program / product	*Name of product or program*	*First clinical problem*	*Real-World Evidence (RWE) from patients in clinical service*	*Analyse data to find out what works and for who*	*Determine most effective dose strength and formulation*	*Start of formal drug registration program*	*Entry on the Australian Register of Therapeutic Goods. Available locally*	*Collect revenues*	*Continuous safety and efficacy monitoring*
Zelira	ZENIVOL	Insomnia							
Zelira	HOPE	Autism							
Emyria	**EMD-003** [1]	**Mental Health / Stress**				Patent filed			
Emyria	**EMD-004** [2]	**IBS**							

Completed

In progress/ planning

1: See ASX announcement 25 NOV 2020 2: See ASX announcement 03 DEC 2020

Emyria's growing treatment portfolio




* Under Australia's Therapeutic Goods Administration (TGA), psychedelic medications such as psilocybin and MDMA are currently Schedule 9 of the Uniform Scheduling of Medicines and Poisons (which deals with Prohibited Substances). They are only available via approved research trials that include oversight by an institutional research ethics committee and careful monitoring and reporting of efficacy and safety outcomes. There is an active rescheduling proposal before TGA so that they can be more easily used as clinical therapies for the treatment of mental illnesses. The rescheduling would move these medicines to Schedule 8 (which deals with Controlled Medicines), the same category as THC-containing cannabinoid medicines. For more information : https://www.tga.gov.au/consultation-invitation/consultation-proposed-amendments-poisons-standard-acms-accs-and-joint-acmsaccs-meetings-november-2020

Emyria's comparative advantages in product development

Key resource	Why it matters	Emyria's unique asset	ASX release
Patients	Patients participate in clinical studies and generate real-world evidence (RWE)	• Over 3,000 patients with unmet needs treated at 5 clinic locations in Australia (at Emyria's own Emerald Clinics) and 1 clinical service partner in UK (Sapphire Medical) • Over 400 referring clinicians	21 OCT 20
Clinical team	Clinical team provides care, generates clinical evidence and provide treatment response insights	• Internationally renowned medical advisory team covering digital health, remote monitoring, pain and psychiatry • 16 GPs all trained in clinical trials	
Data management	Ensures capture of regulator-grade clinical data that can be used as clinical evidence to support drug registration	• Validated clinical and patient-reported assessments • Already collected over 2.5M data points	19 NOV 20
Remote monitoring	Allows remote care of patients, supports telehealth and improves quality and breadth of data gathered	• TGA registered remote monitoring systems • Partnership with Mt Sinai to further develop vital sign tech	15 & 17 SEP 20
In-house analytics	Accelerates insights that inform care models, IP capture and pharmacovigilance	• Multiple PhD-trained analysts and data scientists	19 NOV 20
Intellectual property	Creates barriers to entry	• Emyria's clinical data is a source of unique IP • Patents already filed	25 NOV 20
Global partners	Establishes credibility in larger patient markets and broadens clinical expertise	• UK clinical service provider - Sapphire Medical (London) • USA strategic partner - Mt Sinai (New York) • Largest cannabis company globally - Canopy Growth (Canada) • Partnership with Mind Medicine Australia to develop psychedelic-assisted therapy model	10 AUG 20 & 19 NOV 20

Board with deep clinical expertise

Key Person		Role
	**Dr Stewart Washer** **Cynata** (ASX:CYP) – stem cells **Orthocell** (ASX:OCC) – regenerative medicine **Botanix** (ASX:BOT) – CBD (synthetic)	Chairman & Founder
	**Dr Michael Winlo** Medical doctor Director at **Linear Clinical** Health Lead at **Palantir** MBA from **Stanford** University	Managing Director
	**Dr Alistair Vickery** **Specialist general practitioner** Chair of **Black Swan Health**, - mental health Associate Professor of Primary Health Care	Medical Director
	**Matt Callahan** Founder **Botanix** (ASX:BOT), **Orthocell** 4 products through **FDA approval.** More than **20 years' legal and IP** experience	NED & Founder
	**Professor Sir John Tooke** **Knighted** in the UK for Services to Medicine Senior Independent Director, **BUPA Chile** Head of Medical Sciences at **UCL** Review board of **Google DeepMind** Immediate past President **Academy of Medical Sciences**	Independent NED

Key Metrics

- Last reported cash (Q3, 2020): **$4.2m**
  - **+ $954,000** R&D refund (02 Nov 2020)
- Market cap: **$18.3m** (07 Dec 20)
- Shares on issue **211.4m**
- Options on issue:
  - **18.35m** (strike $0.45)
  - **12m** (strike $0.114)

Emyria positioned to rapidly bring new treatments to patients

Emyria Care → **Emyria Data** → **Emyria Rx**


- **Growing international patient base**
- **Growing care plans & treatment options**

- **Generating unique IP**
- **Creating data deals**

- **High unmet need focus** *(deep pipeline in chronic diseases & mental health)*
- **Via partnerships & independent development**

Emyria's Digital Health Platform

- Develop **TGA registered tech**
- Incorporate best-in-class contactless vital sign technology to develop **digital biomarkers**
- Work with **partners (eg Mt Sinai)** to extend platform capability



myriad data.
individual care.

Contact Information

Michael Winlo: mwinlo@emyria.com

Investors: investors@emyria.com

Media: media@emyria.com

General: info@emyria.com

ASX:EMD

DRAFT